Jonathan Young - 24 Nov 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
24 Nov 2025
Net transactions value
+$290,333
Form type
4
Filing time
26 Nov 2025, 16:03:43 UTC
Previous filing
03 Oct 2025
Next filing
09 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young Jonathan Chief Operating Officer C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young 26 Nov 2025 0001779805

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $90,350 +4,284 +2.2% $21.09 201,182 24 Nov 2025 Direct
transaction AKRO Common Stock Options Exercise $99,990 +3,527 +1.8% $28.35 204,709 24 Nov 2025 Direct
transaction AKRO Common Stock Options Exercise $99,993 +4,739 +2.3% $21.10 209,448 24 Nov 2025 Direct
transaction AKRO Common Stock Gift $0 -9,259 -4.4% $0.000000 200,189 26 Nov 2025 Direct F2
holding AKRO Common Stock 20,000 24 Nov 2025 By EA Irrevocable Trust F1
holding AKRO Common Stock 20,000 24 Nov 2025 By CM Irrevocable Trust F1
holding AKRO Common Stock 20,000 24 Nov 2025 By JL Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -4,284 -100% $0.000000 0 24 Nov 2025 Common Stock 4,284 $21.09 Direct F3
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -3,527 -100% $0.000000 0 24 Nov 2025 Common Stock 3,527 $28.35 Direct F3
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -4,739 -100% $0.000000 0 24 Nov 2025 Common Stock 4,739 $21.10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 Represents shares of the Issuer's Common Stock that the reporting person donated as a gift to a donor advised fund.
F3 The options are vested and currently exercisable.